Overview
Ustar
Biotechnologies (Hangzhou) Ltd. was founded in 2005 and specializes in the
research, development, production, and sales of innovative point-of-care
molecular diagnostic (POCT) technologies and products. The company develops
molecular testing solutions for clinical diagnostics, disease prevention.
Ustar's portfolio
combines molecular diagnostic systems with compatible reagents for nucleic acid
amplification and detection. Its cartridge-based workflow integrates nucleic
acid extraction, purification, and amplification in a fully sealed format, supporting
a simplified sample-in, result-out process.
Expertise in IVD and Molecular Diagnostics
Ustar
Biotechnologies' expertise encompasses the following core capabilities:
Point-of-Care
Molecular Testing: Development of
integrated molecular diagnostic platforms for use across primary healthcare,
hospitals, laboratories, and public-health settings.
Integrated
Nucleic Acid Workflow: Sealed cartridge
technology designed to combine sample processing and nucleic acid amplification
in a streamlined, automated workflow.
Flexible
Testing Platforms MultNAT supports multiplex, drug-resistance, and quantitative testing,
while PortNAT and EasyNAT support different molecular testing workflows and
care settings.Broad Application Coverage: Molecular assays spanning syndromic,
respiratory, gastrointestinal, tuberculosis and emerging infectious diseases,
blood virology, women's and sexual health, tropical fever, hospital-acquired
infections, and livestock and veterinary diseases.
Quality and Innovation:
More than 90 international and domestic patent applications, including 62
granted patents; a GMP-certified clean production workshop; ISO 13485:2016 and
MDSAP certifications; and an expanding international regulatory and market
presence.
Global Presence
Ustar's products and
technologies have served more than 3,000 medical institutions and have been
exported to over 90 countries. The company is headquartered in Hangzhou, China,
and continues to expand molecular testing solutions for healthcare and public-health
needs worldwide.
The company reports
NMPA Class III certification for two devices and more than ten reagents, CE
IVDR certification for more than ten reagents, and additional international
certifications across selected products. Its PortNAT and EasyNAT monkeypox
molecular POCT reagents have also received WHO Emergency Use Listing (EUL).
Partnership with JAT Medical
JAT Medical partners
with Ustar Biotechnologies to expand its IVD and POCT portfolio and bring
molecular diagnostic solutions closer to healthcare providers across Saudi
Arabia.
The collaboration
connects Ustar's molecular testing platforms and reagent technologies with JAT
Medical's local market knowledge, clinical education, technical support, and
healthcare-provider relationships. Together, we aim to support more efficient
diagnostic workflows and more informed clinical decision-making across the
Kingdom.